We are pleased to submit the Outcome of the Board Meeting held on 13/11/2025 for approval of the unaudited quarterly/half year financial statements for the quarter/half year ended on 30/09/2025 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.3 pts more than its Edible Oil peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natraj Proteins' board approved unaudited standalone results for Q2 and H1 FY26 (ended September 30, 2025). For Q2, revenue from operations rose to ₹2,692.17 lakhs from ₹2,278.62 lakhs a year ago (up about 18%), but the company swung to a wider net loss of ₹164.98 lakhs versus ₹101.45 lakhs last year, with EPS at ₹(4.41). For the half-year, revenue declined to ₹5,347.91 lakhs from ₹6,131.76 lakhs (down ~13%), while net loss widened to ₹286.46 lakhs from ₹275.69 lakhs. Despite the losses, operating cash flow stayed positive at ₹159.40 lakhs and cash balance improved sharply to ₹304.12 lakhs (from just ₹6 lakhs at March-end). Statutory auditor Bhutoria Ganesan & Co issued a clean limited review with no qualifications or adverse remarks.
Mixed-to-negative for shareholders: revenue trends are uneven (Q2 up but H1 down) and the company remains loss-making with losses deepening versus the prior year, signalling pressure on margins. However, an improving cash position and a clean auditor review are mild positives; the stock may stay subdued until the company returns to profitability.